Resources
- FDA Approves Palopegteriparatide for Hypoparathyroidism
- ADC in Combination with PD-1: Approvals and Clinical Trials
- Summary of ADC Targets For Solid Tumors & Hematological Tumors
- Advances in TROP-2 Directed ADCs
- Bispecific Antibody Drug Conjugates (ADCs): Emerging Trends
- Maytansinoids as Payloads of ADCs: DM1, DM4
- Nectin-4-Directed Drugs for Solid Tumors
- Claudin18.2 Targeted Therapies In Cancer
- Global Sales of ADCs in 2022 – UP to 7 Billion
- FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx)
